Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.74 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.74 |
| ▸ | CASP1 | P29466 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.74 |
| ▸ | HPGD | P15428 | 3/20 | 0.74 |
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 6/20 | 0.63 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10909733 | 1.00 | TSHR (0.74) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL5836178 | 0.95 | KDM4E (0.68) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL5836646 | 0.95 | KDM4E (0.68) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL1180905 | 0.93 | KDM4E (0.72) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL2949331 | 0.87 | TSHR (0.59) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL1180099 | 0.86 | KDM4E (0.68) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL75219 | 0.86 | ALOX15 (1.00) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL10726923 | 0.86 | ALOX15 (1.00) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL7078511 | 0.86 | KDM4E (0.72) | TSHRALOX15CASP1KDM4EALDH1A1 | |
| SCHEMBL2603426 | 0.86 | KDM4E (0.72) | TSHRALOX15CASP1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | claimed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | claimed |
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | AGRIUS GROUP, LLC. | 2008-01-17 | — | — | US | disclosed |
| WO-2007149395-A2 | 2,5-SUBSTITUTED OXAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF CANCER | AMPHORA DISCOVERY CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| US-4563413-A | PHOTORESISTS, PRINTING PLATES | HERCULES INCORPORATED (US) | 1986-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015193-A1 | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | TSHR 4714/4885ALOX15 2152/4885CASP1 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.